Valeant Pharmaceuticals (VRX.TO) Buy, Sell or…

Valeant Pharmaceuticals (VRX.TO)

0.00

-0.00 (0.00%)

39 watching

TOP PICK

Getting to a yield of almost 14%, sustainable. Almost down to book value. As cheap as you want to be. Attractive to larger companies to buy.

DON'T BUY

Not a fan of this company at all. A 2nd rate company with poor management and poor corporate governance. 10.6% dividend may not be safe.

HOLD

He has a model price of $28.88. That's 110% positive differential. This stock just begs for good news. It needs a catalyst. Thinks around this price is its bottom.

DON'T BUY

He only buys businesses that have positive dynamics and where things are getting better. This company is not in that situation. Wasn't able to perform well during reasonably good markets and is having a rougher time in more difficult markets.

WAIT

Has been down for a while and has been a big disappointment. Money is flowing into healthcare and is regarded as a defensive sector. Chart looks like a falling wedge, which is bullish. Wait to see if it breaks out and in volume.

WATCH

FDA refused to give an extended use-release approval for its existing drug. Just announced that Havenol is going to be distributed by Johnson & Johnson (JNJ-N), so maybe it's turning. Operational side of things have improved enormously. Sold his holdings.

SELL

(Market Call Minute.) Would need more of a pipeline before he would even be interested.

COMMENT

His model price is $30.83 giving it 125% positive differential. He sees 08 earnings at $1.54. Bad news is basically shadowing this stock. It is probably at its low, discounting any more bad news. Any good news and it should pop. Frustrating stock.

BUY

Their Welbutrin is facing competition from generic drugs. Almost 10% yield, which he feels is not sustainable. However, the stock has come down a long way and they have a pipeline that is starting to build into 2009. Have lots of cash on the balance sheet.

DON'T BUY

Model price is $29.68 but that doesn’t include recent bad news. Its next level is $13.30. This space is terrible at this time.

DON'T BUY

This has been a hard stock to make money in. Has had some management and product issues. Investor’s confidence in the stock has been very low.

WAIT

Market Call Minute - Interesting, but it keeps going down and making new lows.

SELL

There “pipeline” of new drugs is very bare. Having trouble getting market penetration with their new stuff.

DON'T BUY

Trouble written all over it. 90% differential. Needs positive news somewhere. Interesting to have in securities portfolio.

DON'T BUY

Got rid of their US sales force. Their key drug Welbutrin is running off protection and will have more competition in 2008. Reasonably cheap. FDA delayed one drug. There will be volatility.

Showing 286 to 300 of 714 entries

Most Recent Experts

The Panic-Proof Portfolio (Stockchase Research)

Stockchase Premium

Keith Richards

ValueTrend Wealth Management

Joe Terranova

Virtus Investment Partners

Stephen Weiss, Founder, Short Hills Capital Partners

Short Hills Capital Partners

Rob Sechan, Managing Partner, New Edge Capital

New Edge Capital

Stockchase, in its reporting on what has been discussed by individuals on business television programs (in particular Business News Network), neither recommends nor promotes any investment strategies.

We paraphrase the experts by hand, we watch the shows and write down what we understood from the experts’ comments. We are human and can make mistakes, help us fix any errors. If you see something that you know is not right or if there is a problem with the site, feel free to email us at : [email protected].

Summer Sale

Valeant Pharmaceuticals (VRX.TO)